Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CI, LLY, THC, BSX, ELV, and represent 19.70% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: COO (+$31M), CI (+$21M), ALGN (+$16M), ELV (+$16M), OSCR (+$14M), DXCM (+$13M), RPRX (+$12M), PEN (+$10M), MDGL (+$9.7M), AXSM (+$8.3M).
- Started 22 new stock positions in KRYS, BRKR, COO, JANX, PODD, AVTR, PLRX, AUGX, SYK, ALGN. NVCR, SNDX, MIRM, AMGN, PEN, ACHC, EHC, RGEN, Alpine Immune Sciences, MDGL, KURA, NARI.
- Reduced shares in these 10 stocks: LLY (-$36M), HUM (-$24M), CVS (-$21M), Cooper Companies (-$19M), COR (-$19M), MCK (-$15M), AXNX (-$13M), BMRN (-$12M), DHR (-$12M), LNTH (-$12M).
- Sold out of its positions in ALLO, AXNX, BNTX, CVS, Cooper Companies, EW, EVH, HRMY, HCAT, HUM. ImmunoGen, Karuna Therapeutics Ord, LNTH, MRSN, Mirati Therapeutics, MRNA, OLK, OM, RCM, TXG, VEEV, WST, MGTX.
- Rhenman & Partners Asset Management AB was a net seller of stock by $-71M.
- Rhenman & Partners Asset Management AB has $1.1B in assets under management (AUM), dropping by 13.75%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 84 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cigna Corp (CI) | 4.7 | $50M | +71% | 137k | 363.19 |
|
| Eli Lilly & Co. (LLY) | 4.0 | $42M | -45% | 54k | 777.96 |
|
| Tenet Healthcare Corp Com New (THC) | 3.8 | $40M | +13% | 380k | 105.11 |
|
| Boston Scientific Corporation (BSX) | 3.8 | $40M | -16% | 582k | 68.49 |
|
| Anthem (ELV) | 3.4 | $36M | +82% | 70k | 518.54 |
|
| Abbvie (ABBV) | 3.3 | $35M | +26% | 190k | 182.10 |
|
| Hca Holdings (HCA) | 3.2 | $33M | +20% | 100k | 333.53 |
|
| Regeneron Pharmaceuticals (REGN) | 3.1 | $33M | -14% | 34k | 962.49 |
|
| Cooper Cos (COO) | 2.9 | $31M | NEW | 301k | 101.46 |
|
| Merck & Co (MRK) | 2.7 | $29M | +15% | 219k | 131.95 |
|
| Becton, Dickinson and (BDX) | 2.7 | $29M | +22% | 116k | 247.45 |
|
| Medtronic SHS (MDT) | 2.7 | $28M | -13% | 325k | 87.15 |
|
| Oscar Health Cl A (OSCR) | 2.4 | $25M | +119% | 1.7M | 14.87 |
|
| Procept Biorobotics Corp (PRCT) | 2.3 | $24M | 487k | 49.42 |
|
|
| McKesson Corporation (MCK) | 2.2 | $24M | -38% | 44k | 536.85 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.2 | $24M | -26% | 57k | 418.01 |
|
| Natera (NTRA) | 2.1 | $22M | -10% | 240k | 91.46 |
|
| Abbott Laboratories (ABT) | 2.0 | $21M | -29% | 185k | 113.66 |
|
| Shockwave Med | 2.0 | $21M | -20% | 64k | 325.63 |
|
| BioMarin Pharmaceutical (BMRN) | 2.0 | $21M | -37% | 238k | 87.34 |
|
| Intuitive Surgical Com New (ISRG) | 1.9 | $20M | -25% | 51k | 399.09 |
|
| UnitedHealth (UNH) | 1.9 | $20M | -11% | 41k | 494.70 |
|
| Dex (DXCM) | 1.8 | $19M | +207% | 139k | 138.70 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.7 | $18M | +2% | 147k | 120.42 |
|
| Royalty Pharma Shs Class A (RPRX) | 1.6 | $17M | +263% | 545k | 30.37 |
|
| Align Technology (ALGN) | 1.6 | $16M | NEW | 50k | 327.92 |
|
| Dynavax Technologies Corp Com New (DVAX) | 1.4 | $14M | +65% | 1.2M | 12.41 |
|
| Iovance Biotherapeutics (IOVA) | 1.3 | $14M | 955k | 14.82 |
|
|
| Cytokinetics Com New (CYTK) | 1.3 | $14M | 198k | 70.11 |
|
|
| Biogen Idec (BIIB) | 1.2 | $12M | 57k | 215.63 |
|
|
| Viking Therapeutics (VKTX) | 1.1 | $12M | -19% | 145k | 82.00 |
|
| Axsome Therapeutics (AXSM) | 1.1 | $12M | +258% | 144k | 79.80 |
|
| Apellis Pharmaceuticals (APLS) | 1.0 | $11M | -17% | 178k | 58.78 |
|
| AmerisourceBergen (COR) | 1.0 | $10M | -64% | 43k | 242.99 |
|
| Penumbra (PEN) | 1.0 | $10M | NEW | 46k | 223.18 |
|
| Centene Corporation (CNC) | 1.0 | $10M | +330% | 129k | 78.48 |
|
| Alignment Healthcare (ALHC) | 1.0 | $10M | +68% | 2.0M | 4.96 |
|
| EXACT Sciences Corporation (EXAS) | 0.9 | $9.9M | -10% | 143k | 69.06 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.9 | $9.7M | NEW | 37k | 267.04 |
|
| Intra Cellular Therapies (ITCI) | 0.9 | $9.5M | +44% | 138k | 69.20 |
|
| Gilead Sciences (GILD) | 0.9 | $9.3M | -45% | 127k | 73.25 |
|
| Inspire Med Sys (INSP) | 0.9 | $9.0M | +500% | 42k | 214.79 |
|
| Zimmer Holdings (ZBH) | 0.8 | $8.9M | +12% | 68k | 131.98 |
|
| Neurocrine Biosciences (NBIX) | 0.8 | $8.1M | +8% | 59k | 137.92 |
|
| Iqvia Holdings (IQV) | 0.7 | $7.8M | -34% | 31k | 252.89 |
|
| Novocure Ord Shs (NVCR) | 0.7 | $7.7M | NEW | 495k | 15.63 |
|
| Essa Pharma Com New (EPIX) | 0.7 | $7.7M | +155% | 912k | 8.49 |
|
| Thermo Fisher Scientific (TMO) | 0.7 | $7.6M | +2500% | 13k | 581.21 |
|
| Arvinas Ord (ARVN) | 0.7 | $7.0M | +100% | 170k | 41.28 |
|
| Nuvalent Inc-a (NUVL) | 0.6 | $6.6M | 88k | 75.09 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 0.6 | $6.3M | -6% | 42k | 149.45 |
|
| Insulet Corporation (PODD) | 0.6 | $6.0M | NEW | 35k | 171.40 |
|
| Immunocore Hldgs Ads (IMCR) | 0.5 | $5.2M | -10% | 80k | 65.00 |
|
| Xencor (XNCR) | 0.5 | $4.8M | -2% | 219k | 22.13 |
|
| Avantor (AVTR) | 0.4 | $4.4M | NEW | 171k | 25.57 |
|
| Syndax Pharmaceuticals (SNDX) | 0.4 | $4.2M | NEW | 179k | 23.80 |
|
| Immunovant (IMVT) | 0.4 | $4.1M | -24% | 126k | 32.31 |
|
| Janux Therapeutics (JANX) | 0.4 | $3.9M | NEW | 105k | 37.65 |
|
| Kura Oncology (KURA) | 0.3 | $3.6M | NEW | 167k | 21.33 |
|
| Revance Therapeutics (RVNC) | 0.3 | $3.5M | +94% | 702k | 4.92 |
|
| Charles River Laboratories (CRL) | 0.3 | $3.4M | -71% | 13k | 270.95 |
|
| Alpine Immune Sciences | 0.3 | $3.4M | NEW | 86k | 39.64 |
|
| Krystal Biotech (KRYS) | 0.3 | $3.4M | NEW | 19k | 177.93 |
|
| Augmedix (AUGX) | 0.3 | $3.3M | NEW | 800k | 4.09 |
|
| Bridgebio Pharma (BBIO) | 0.3 | $3.2M | -22% | 105k | 30.92 |
|
| Alkermes SHS (ALKS) | 0.3 | $3.0M | -70% | 110k | 27.07 |
|
| Stryker Corporation (SYK) | 0.3 | $2.9M | NEW | 8.0k | 357.87 |
|
| Danaher Corporation (DHR) | 0.3 | $2.7M | -81% | 11k | 249.72 |
|
| Inari Medical Ord (NARI) | 0.3 | $2.7M | NEW | 56k | 47.98 |
|
| Glaukos (GKOS) | 0.2 | $2.5M | -63% | 27k | 94.29 |
|
| Encompass Health Corp (EHC) | 0.2 | $2.4M | NEW | 29k | 82.58 |
|
| Mirum Pharmaceuticals (MIRM) | 0.2 | $2.3M | NEW | 92k | 25.12 |
|
| Privia Health Group (PRVA) | 0.2 | $2.2M | -75% | 114k | 19.59 |
|
| Pliant Therapeutics (PLRX) | 0.2 | $2.2M | NEW | 145k | 14.90 |
|
| Inmune Bio Ord (INMB) | 0.2 | $2.1M | 178k | 11.75 |
|
|
| Relay Therapeutics (RLAY) | 0.2 | $1.9M | +21% | 230k | 8.30 |
|
| Igm Biosciences (IGMS) | 0.2 | $1.9M | -2% | 195k | 9.65 |
|
| Bruker Corporation (BRKR) | 0.2 | $1.9M | NEW | 20k | 93.94 |
|
| Tg Therapeutics (TGTX) | 0.2 | $1.9M | -22% | 124k | 15.21 |
|
| Intellia Therapeutics (NTLA) | 0.1 | $1.3M | -4% | 48k | 27.51 |
|
| Amgen (AMGN) | 0.1 | $1.2M | NEW | 4.3k | 284.32 |
|
| Bio-techne Corporation (TECH) | 0.1 | $1.1M | -62% | 16k | 70.39 |
|
| Acadia Healthcare (ACHC) | 0.1 | $1.0M | NEW | 13k | 79.22 |
|
| Repligen Corporation (RGEN) | 0.1 | $920k | NEW | 5.0k | 183.92 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2024 Q1 filed May 14, 2024
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022
- Rhenman & Partners Asset Management AB 2022 Q2 filed Aug. 12, 2022
- Rhenman & Partners Asset Management AB 2022 Q1 filed May 13, 2022
- Rhenman & Partners Asset Management AB 2021 Q4 filed Feb. 11, 2022
- Rhenman & Partners Asset Management AB 2021 Q3 filed Nov. 12, 2021
- Rhenman & Partners Asset Management AB 2021 Q2 filed Aug. 13, 2021
- Rhenman & Partners Asset Management AB 2021 Q1 filed May 14, 2021
- Rhenman & Partners Asset Management AB 2020 Q4 filed Jan. 19, 2021
- Rhenman & Partners Asset Management AB 2020 Q3 filed Oct. 13, 2020
- Rhenman & Partners Asset Management AB 2020 Q2 filed July 16, 2020